High Ep-CAM Expression is Associated with Poor Prognosis in Node-positive Breast Cancer
- 214 Downloads
Previous studies in small series of patients with invasive breast cancer suggested a prognostic value of Ep-CAM overexpression in primary tumor tissue. To corroborate these findings, we performed a retrospective analysis of Ep-CAM expression using a tissue microarray containing tissue specimens from a large patient set. Ep-CAM expression was evaluated by immunohistochemistry in breast cancer tissue from 1715 patients with documented raw survival data. High level Ep-CAM expression (overexpression) was found in 41.7% of tumor samples, low level expression was found in 48.0% and no expression in 10.3% of tumor samples. Ep-CAM expression predicted poor overall survival in this patient cohort (p < 0.0001). Overall survival decreased significantly with increasing Ep-CAM expression. However, in this patient sample Ep-CAM expression was not an independent prognostic marker by multivariate analysis. Subgroup analysis revealed that Ep-CAM expression was a prognostic marker in node-positive (p < 0.0001) but not in node-negative (p= 0.58) breast cancer patients. Intriguingly, Ep-CAM expression was predictive for a dismal prognosis in patients receiving adjuvant cytotoxic (p= 0.03) or hormonal therapy (p < 0.0001) but not in untreated patients (p= 0.41). In summary, this study provides strong evidence that expression of Ep-CAM is a powerful marker of poor prognosis in node-positive invasive breast carcinoma and a potential predictive marker of sensitivity to adjuvant hormonal and/or cytotoxic treatment modalities.
Unable to display preview. Download preview PDF.
- 5.Cirulli V, Crisa L, Beattie GM, Mally MI, Lopez AD, Fannon A, Ptasznik A, Inverardi L, Ricordi C, Deerinck T, Ellisman M, Reisfeld RA, Hayek A: KSA antigen Ep–CAM mediates cell–cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140: 1519–1534, 1998CrossRefPubMedGoogle Scholar
- 9.Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R: Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven–year outcome of a multicenter randomized trial. J Clin Oncol 16: 1788–1794, 1998PubMedGoogle Scholar
- 14.Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon–Cardo C: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158: 1245–1251, 2001PubMedGoogle Scholar
- 15.Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, Sauter G: Patterns of her–2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 93: 1141–1146, 2001CrossRefPubMedGoogle Scholar
- 21.Schon MP, Schon M, Klein CE, Blume U, Bisson S, Orfanos CE: Carcinoma–associated 38–kD membrane glycoprotein MH 99/KS 1/4 is related to proliferation and age of transformed epithelial cell lines. J Invest Dermatol 102: 987–991, 1994 22. de Boer CJ, van Krieken JH, Janssen–van Rhijn CM, Litvinov SV: Expression of Ep–CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 188: 201–206, 1999CrossRefPubMedGoogle Scholar
- 23.Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL: Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin–positive tumor cells in bone marrow. Clin Cancer Res 5: 3999–4004, 1999PubMedGoogle Scholar